

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Biomedical Sciences Investment Fund Pte Ltd.</u> (Last) (First) (Middle) 20 BIOPOLIS WAY #09-01 (Street) SINGAPORE 138668 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Vanda Pharmaceuticals Inc. [VNDA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 04/18/2006	
		6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/18/2006		C		1,479,867 ⁽³⁾	A	(1)	1,481,347 ⁽³⁾	I ⁽⁶⁾	See Footnote ⁽⁶⁾
Common Stock	04/18/2006		C		1,091,321 ⁽³⁾	A	(2)	2,572,668 ⁽³⁾	I ⁽⁶⁾	See Footnote ⁽⁶⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series A Preferred Stock	(1)	04/18/2006		C		4,898,000		(4)	(5)	Common Stock	1,479,867 ⁽³⁾	(1)	0	I ⁽⁶⁾	See Footnote ⁽⁶⁾
Series B Preferred Stock	(2)	04/18/2006		C		3,612,009		(4)	(5)	Common Stock	1,091,321 ⁽³⁾	(2)	0	I ⁽⁶⁾	See Footnote ⁽⁶⁾

1. Name and Address of Reporting Person*
Biomedical Sciences Investment Fund Pte Ltd.
 (Last) (First) (Middle)
 20 BIOPOLIS WAY
 #09-01
 (Street)
 SINGAPORE 138668
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Bio One Capital Pte Ltd.
 (Last) (First) (Middle)
 20 BIOPOLIS WAY
 #09-01
 (Street)
 SINGAPORE 138668
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
EDB Investments Pte Ltd.

(Last)	(First)	(Middle)
20 BIOPOLIS WAY		
#09-01		
<hr/>		
(Street)		
SINGAPORE		138668
<hr/>		
(City)	(State)	(Zip)

Explanation of Responses:

1. Reflects the automatic conversion of each share of the Series A Preferred Stock into one share of Common Stock upon the close of business of the day immediately preceding the closing of the issuer's initial public offering.
2. Reflects the automatic conversion of each share of the Series B Preferred Stock into one share of Common Stock upon the close of business of the day immediately preceding the closing of the issuer's initial public offering.
3. Reflects a 1-for-3.309755 reverse stock split to occur immediately following the effectiveness of the registration statement covering the issuer's initial public offering.
4. Immediately.
5. Not Applicable.
6. Securities owned directly by Biomedical Sciences Investment Fund Pte. Ltd. These securities may be deemed to be beneficially owned by Bio*One Capital Pte Ltd. ("BioOne"), the fund manager of BioMedical Science Investment Fund PTE LTD ("BSIF") and EDB Investments Pte Ltd. ("EDB"), the parent company of BSIF and BioOne. Each of BioOne and EDB disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that BioOne or EDB is the beneficial owner of the securities any purpose, except to the extent of its pecuniary interest therein.

/s/ Sze Kuan Sim, Authorized
Signatory

04/18/2006

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Sze Kuan Sim has signed certain of these documents as an authorized signatory. Note that copies of the applicable Statement Appointing Designated Filer and Authorized Signatories are already on file with the appropriate agencies.

JOINT FILER INFORMATION

Joint Filer Name:
Bio*One Capital Pte Ltd.

Relationship to Issuer: 10% Owner

Address: 20 Biopolis Way, #09-01 Centros, Singapore 138668

Designated Filer: Biomedical Sciences Investment Fund Pte Ltd.

Date of Event
Requiring Statement: April 18, 2006

Issuer Name
and Ticker
or Trading Symbol: Vanda Pharmaceuticals Inc. (VNDA)

Signature Bio*One Capital Pte Ltd.

By: /s/ Sze Kuan Sim

Sze Kuan Sim,

Authorized Signatory

Joint Filer Name: EDB Investments Pte Ltd.

Relationship to Issuer: 10% Owner

Address: 20
Biopolis Way, #09-01 Centros, Singapore 138668

Designated Filer:
Biomedical Sciences Investment Fund Pte Ltd.

Date of Event
Requiring Statement: April 18, 2006

Issuer Name and Ticker
or
Trading Symbol: Vanda Pharmaceuticals Inc. (VNDA)

Signature EDB
Investments Pte Ltd.

By: /s/ Sze Kuan Sim

Sze Kuan Sim, Authorized

Signatory